114 related articles for article (PubMed ID: 3907938)
1. When is autologous bone marrow transplantation safe after high-dose treatment with etoposide?
Littlewood TJ; Spragg BP; Bentley DP
Clin Lab Haematol; 1985; 7(3):213-8. PubMed ID: 3907938
[TBL] [Abstract][Full Text] [Related]
2. High-dose etoposide with autologous bone marrow transplantation as initial treatment of small cell lung cancer--a negative report.
Littlewood TJ; Bentley DP; Smith AP
Eur J Respir Dis; 1986 May; 68(5):370-4. PubMed ID: 3015650
[TBL] [Abstract][Full Text] [Related]
3. Simple method for the administration of high-dose etoposide during autologous bone marrow transplantation.
Lazarus HM; Creger RJ; Diaz D
Cancer Treat Rep; 1986 Jun; 70(6):819-20. PubMed ID: 3524832
[No Abstract] [Full Text] [Related]
4. Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation.
Sculier JP; Klastersky J; Stryckmans P
J Clin Oncol; 1985 Feb; 3(2):184-91. PubMed ID: 2981983
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of high-dose etoposide, high-dose cisplatin, and reinfusion of autologous bone marrow for lung cancer.
Lazarus HM; Spitzer TR; Creger RJ
Am J Clin Oncol; 1990 Apr; 13(2):107-12. PubMed ID: 2156415
[TBL] [Abstract][Full Text] [Related]
6. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
[TBL] [Abstract][Full Text] [Related]
7. Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation.
Ciobanu N; Paietta E; Andreeff M; Papenhausen P; Wiernik PH
Exp Hematol; 1986 Aug; 14(7):626-35. PubMed ID: 3525202
[TBL] [Abstract][Full Text] [Related]
8. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Sniecinski I
Cancer; 1994 Jan; 73(1):125-34. PubMed ID: 7903906
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of high dose VP 16-213 as single agent or in combination with cyclophosphamide and autologous bone marrow transplantation (ABMT).
Mulder NH; Meinesz AF; Sleijfer DT; Postmus PE; De Vries EG; Van der Geest S; Orie JL; Vriesendorp R
Neth J Med; 1984; 27(10):389-92. PubMed ID: 6096742
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics of high-dose etoposide after short-term infusion.
Köhl P; Köppler H; Schmidt L; Fritsch HW; Holz J; Pflüger KH; Jungclas H
Cancer Chemother Pharmacol; 1992; 29(4):316-20. PubMed ID: 1537079
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
[TBL] [Abstract][Full Text] [Related]
12. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.
Wolff SN; Fer MF; McKay CM; Hande KR; Hainsworth JD; Greco FA
J Clin Oncol; 1983 Nov; 1(11):701-5. PubMed ID: 6366131
[TBL] [Abstract][Full Text] [Related]
13. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
[TBL] [Abstract][Full Text] [Related]
14. Infusion of high doses of undiluted etoposide through central venous catheters during preparation for bone marrow transplantation.
Creger RJ; Fox RM; Lazarus HM
Cancer Invest; 1990; 8(1):13-6. PubMed ID: 2161702
[TBL] [Abstract][Full Text] [Related]
15. High-dose etoposide and autologous bone marrow transplantation as intensification treatment in small cell lung cancer: a pilot study.
Marangolo M; Rosti G; Amadori D; Leoni M; Ardizzone A; Fiorentini G; Cruciani G; Tienghi A; Ravaioli A; Sebastiani L
Bone Marrow Transplant; 1989 Jul; 4(4):405-8. PubMed ID: 2550104
[TBL] [Abstract][Full Text] [Related]
16. Autografting with bone marrow exposed to multiple courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophosphamide in vitro.
Kushner BH; Gulati SC; O'Reilly RJ; Heller G; Cheung NK
Med Pediatr Oncol; 1990; 18(6):454-8. PubMed ID: 2135871
[TBL] [Abstract][Full Text] [Related]
17. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF
J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
[TBL] [Abstract][Full Text] [Related]
18. High-dose etoposide (VP-16) in small-cell lung cancer.
Greco FA; Johnson DH; Hande KR; Porter LL; Hainsworth JD; Wolff SN
Semin Oncol; 1985 Mar; 12(1 Suppl 2):42-4. PubMed ID: 2983434
[TBL] [Abstract][Full Text] [Related]
19. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
Johnson DH; Wolff SN; Hainsworth JD; Porter LL; Grosh WW; Hande KR; Greco FA
J Clin Oncol; 1985 Feb; 3(2):170-5. PubMed ID: 2981981
[TBL] [Abstract][Full Text] [Related]
20. Etoposide (VP-16-213).
Issell BF; Crooke ST
Cancer Treat Rev; 1979 Jun; 6(2):107-24. PubMed ID: 385138
[No Abstract] [Full Text] [Related]
[Next] [New Search]
